Core Viewpoint - The company plans to acquire 100% of Hangzhou Lanran's shares through a combination of issuing shares and cash payments, while also raising up to 1 billion yuan in supporting funds [1] Group 1: Acquisition Details - The acquisition involves 19 counterparties, including Xiamen Puyu Investment Partnership and individuals Lou Yongtong and Qing Bo [1] - The total amount of supporting funds raised will not exceed 1 billion yuan, which is capped at 100% of the transaction price for the asset purchase through share issuance [1] Group 2: Target Company Overview - Hangzhou Lanran focuses on research and application of electrodialysis technology, primarily engaged in the R&D, production, sales, and technical services of ion exchange membranes and related equipment [1] - The company has established a comprehensive electrodialysis industry chain, covering membrane materials, ion exchange membranes, membrane components, electrodialysis equipment, control systems, and integrated electrodialysis application devices [1] Group 3: Strategic Implications - Post-acquisition, the listed company will enhance its capability to provide a combined process of "pressure-driven + electric-driven" membrane technology solutions to customers [1] - The company's stock will resume trading on December 1, 2025, following the application to the Shenzhen Stock Exchange [1]